New intravenous combination antibiotic for intra-abdominal and urinary tract infection

Zerbaxa contains the cephalosporin ceftolozane and the beta-lactamase inhibitor tazobactam.

Ceftolozane/tazobactam is effective against bacteria including Enterobacter cloacae, Escherichia coli and Klebsiella pneumoniae. | iStock
Ceftolozane/tazobactam is effective against bacteria including Enterobacter cloacae, Escherichia coli and Klebsiella pneumoniae. | iStock

Further information
View Zerbaxa drug record 
Summary of Product Characteristics
Manufacturer: Merck Sharp & Dohme

The combination is administered by intravenous infusion and is indicated for the treatment of complicated intra-abdominal infection, complicated urinary tract infection and acute pyelonephritis. Susceptible organisms include Enterobacter cloacae, Escherichia coli and Klebsiella pneumoniae.

In a trial in patients with complicated intra-abdominal infection, clinical cure rates for the ceftolozane/tazobactam combination were 95.9% in patients younger than 65 years (n=293) and 87.8% in those 65 years or older (n=82).

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

Cases of necrotising fasciitis of the genitalia or...

New advice for carbimazole over malformation and pancreatitis risks

New advice for carbimazole over malformation and pancreatitis risks

Reports of congenital malformations and acute pancreatitis...

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Antibiotic Treatments in Adults, Summary of Regimens

Antibiotic Treatments in Adults, Summary of Regimens

Dose regimens for common bacterial infections.